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This special issue of PPAR Research is dedicated to “PPARs,
RXRsandDrugMetabolizingEnzymes”.KnowledgeofPPAR
biology, over the past ﬁve years, has dramatically increased
our understanding of the potential therapeutic usefulness
of these receptors in metabolic alterations associated with
disease process of alcoholic and non-alcoholic fatty liver
disease and metabolic syndrome. In addition, the utility of
PPARagonistinthetreatmentofliverdiseasebynormalizing
hypertriglyceridemia, dyslipidemia, and the toxic eﬀects of
bile acids has a sound scientiﬁc basis in the ability of PPAR
receptors to control lipid oxidation and disposal as well as
regulatorsofhepaticinﬂammation.Furtherinsightintoboth
the indirect and direct eﬀects of dual and pan PPAR agonist
may potentiate the development of new therapeutic modal-
ities to treat fatty acid oxidation disorders, dyslipidemia,
inﬂammation, and bile acid accumulation associated with
several liver diseases and metabolic syndrome.
Articles included in this special issue highlight the imp-
ortance of PPARs and RXR in drug metabolism and hepatic
diseases associated with metabolic disorders. Alterations in
drug metabolizing gene expression in diﬀerent disease sta-
tes due to the diﬀerential expression of PPAR isoforms hig-
hlights the importance of PPAR in disease progression
and as therapeutic target in the amelioration of disease
progression. The ﬁrst review summarizes past and new
developments in alcoholic fatty liver disease (ALD) and how
PPAR/RXR regulates phase I enzymes in alcohol metabolism
and the redox balance of cells. The direct impairment
of PPAR by acetaldehyde results in reduction of NAD+
pool leading to alterations in lipid metabolism, increased
oxidative stress, and increased pro-inﬂammatory cytokines,
chemokines and acute phase proteins, which may be central
in the onset and perpetuation of mechanism in the clinical
progression of alcoholic liver disease (ALD).A second review
focuses on the role of PPAR isoforms in the regulation of
bile acid and cholesterol metabolism, with speciﬁc insight
into how PPARα regulates bile acid synthesis, conjugation,
and transport by phase II and III enzymes. This review
also provides an updated report on how PPARs regulate
cholesterol synthesis, absorption, and reverse cholesterol
transport, and how PPAR agonist may be used to treat
cholestatic liver disease. This review also raises important
questions concerning the use of PPAR agonist in treating
bile acid accumulation in several liver diseases, which leads
to hepatocyte injury, impaired liver metabolic function,
progressing to liver ﬁbrosis and cirrhosis. Further research
needs to focus on how selective PPAR agonist and isoforms
regulated bile acid conjugation and thereby prevent bile acid
toxicity observed in cholestastic disease. The conjugation of
bile acids by UDP-glucuronosyltransferase, a PPAR target
gene further emphasizes the importance of PPAR in bile
acid toxicity. In addition, induction of the sulfotransferase
genes by PPAR and sulfonation of cholesterol in keratinocyte
diﬀerentiation suggests that these phase II genes have
an important role in epidermal wound healing. Finally,
although numerous studies in animal models of disease have
dramatically increased our understanding of how PPARs not
only regulate drug metabolism and the elimination of drugs
and toxic endogenous metabolities in disease progression,
the application of these results to human in the design
of eﬀective PPAR agonist has all too often led to adverse
drug interactions and unacceptable drug toxicity. A fourth
review in this series details the exciting possibility of using
a human hepatocyte chimeric mouse model to predict
metabolism and possible eﬀectiveness of new PPAR agonist
in humans. The investigators clearly show the utility of2 PPAR Research
this model system by the increased phosphatidylcholine
transport into bile canaliculi through induction of human
ABCB4 transporter by benzaﬁbrate activation of PPAR.
There are marked species diﬀerences in genes and proteins
associated with the absorption, distribution, metabolism,
and excretion (ADME) of xenobiotics and drugs, thus the
human hepatocyte chimeric mice may not only be used for
increasing the safety and eﬀectiveness of lead drugs, but
may also serve as a model system to study human liver
disease and assess the potency and eﬃcacy of dual and pan
PPAR agonist in preventing or delaying disease progression.
The ﬁnal review in these series details how fatty acids are
partitioned by fatty acid transport proteins to either anabolic
or catabolic pathways regulated by PPARs, and explores how
medium chain fatty acid (MCFA) CYP4A and long chain
fatty acid (LCFA) CYP4F ω-hydroxylase genes are regulated
infattyliver.Theauthorsproposeahypothesisthatincreased
CYP4A expression with a decrease in CYP4F genes may pro-
mote the progression of steatosis to steatohepatitis.
We thank the editors for the opportunity to share with
other investigators these interesting reviews on drug metab-
olizing genes regulated by PPAR/RXR. It is apparent that
drug metabolizing genes not only play a pivotal role in drug
eﬃcacy, drug toxicity, and adverse drug reactions, but also a
critical and crucial role in the development and progression
liver disease. Therefore, understanding how the PPAR genes
and other hormone nuclear receptors are regulated during
disease processes will provide us the opportunity to design
eﬀective therapeutic modalities to treat disease by the ina-
ctivation, conjugation, and transport of toxic endogenous
metabolities.
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